CN
Product Service Diagnosis and Treatment BGI PARP Inhibitor CDx-HRR Genetic Test
The change in molecular markers from BRCA to HRR significantly improves the positivity rate
BRCA1/2 genes are core genes in the pathway of homologous recombination repair (HRR), and their deleterious variants significantly increase the risk of breast, ovarian, pancreatic, prostate, and other related cancers. They can serve as molecular markers to help patients and their healthcare providers to make a personalized diagnosis and select a precise treatment plan.
As clinical research advances, more genes in the HRR pathway have shown similar functions. For example, tHRR has a positive mutation rate of 27.9% (where BRCA2 accounts for 8.7% and BRCA1 1%) in overall prostate cancer patients (2,792 cases)[1].
Distribution of HRR gene mutations in different solid cancers (n=17,566)[2]
BRCA genetic testing standards and specifications are gradually improved
• It is difficult to test HRR genes such as BRCA1/2 because no hotspot mutations have been found in these genes and variants spread over their entire coding regions. Therefore, high-throughput sequencing technology is required to perform a comprehensive evaluation of these genes.
• The test should cover the coding regions as well as ±20bp into the intronic regions to avoid missing relevant fusion events.
• Since high-throughput sequencing could miss highly pathogenic large-scale rearrangements, MLPA is required as a complementary test to make a better diagnosis.
• Both cancer tissue and blood need to be tested, in order to identify a higher proportion of people who could benefit from the use of PARP inhibitors.
BGI PARP Inhibitor CDx-HRR Genetic Test
The test is used to detect 68 genes, including BRCA1/2, in the homologous recombinant signaling pathway using cancer tissue (paraffin sections) and/or peripheral blood from cancer patients as samples. It's specifically designed to assess the efficacy of PARP inhibitors and the risk of associated hereditary cancer syndromes.
Product features
Detect content
Test objectives
·To aid screening for patients with ovarian, breast, pancreatic, and prostate cancers suitable for PARP inhibitors
·To predict sensitivity to platinum-based chemotherapy drugs
·To predict the risk of cancer recurrence after treatment
·To provide information on the genetic susceptibility risk for related cancers for relatives of patients
Suitable for

    Patients with ovarian, breast, pancreatic and prostate cancers

Sample requirements

    Blood-based test: 5mL of blood
    Cancer tissue testing: fresh tissue from surgery
    60 mg (the size of a soybean seed) or 10 FFPE sections + 5mL of blood

References

Customer Service:

+1 866 301 0097

Service Time:7*24

Language:English

E-mail: info@bgi.com

Copyright © BGI 2022. All Rights Reserved. Guangdong ICP Registration No. 16021117